RNA epitranscriptomics, the study of RNA modifications (pseudouridine (?), 5-methylcytidine (m5C), N1-methyladenosine (m1A), N4-acetylcytidine (ac4C), ribose methylations (Nm) and N 7-methylguanosine (m7G), etc.), is the new frontier of the field. Despite being known since the 1970s, eukaryotic RNA modifications were mostly identified on transfer RNA and ribosomal RNA until the last decade, when they have been identified and characterized on mRNA and various non-coding RNAs. Increasing evidence suggests that RNA modification pathways are also mis-regulated in human diseases and may be ideal targets of disease therapy.
Cells may die from accidental cell death (ACD) or regulated cell death (RCD). ACD is a biologically uncontrolled process, whereas RCD involves tightly structured signaling cascades and molecularly defined effector mechanisms. A growing number of novel non-apoptotic forms of RCD (necroptosis, pyroptosis, ferroptosis, etc.) have been identified and are increasingly being implicated in various human pathologies. RNA modifications can regulate RNA stability and translation and are thus involved in multiple biological activities. Recently, RNA modifications have been shown to have important roles in non-apoptotic forms of RCD.
In this Research Topic, we will concentrate on collecting latest updates about the roles and mechanisms of epitranscriptomic RNA modifications in non-apoptotic forms of RCD in multiple diseases. Also, we highlight the regulatory functions of different RNA modification regulators in the progression or suppression of RCD events and the targeting of these regulators as a potential therapeutic approach for human diseases. We anticipate that our Research Topic will help expand the research community’s knowledge about this recent and rapidly developing field of “epitranscriptomic RNA modification in non-apoptotic forms of regulated cell death” for further thorough studies, which will certainly help manage human diseases.
This Research Topic welcomes all article types. Though not limited to these entirely, we encourage the submission of manuscripts related to the following specific themes:
1. Roles of RNA modifications in non-apoptotic forms of RCD.
2. Biological regulatory mechanisms of RNA modifications in non-apoptotic forms of RCD.
3. The links between RNA modifications and different non-apoptotic forms of RCD pathways in the initiation, progression and therapeutic resistance of human diseases.
4. Clinical application of the target-based RNA modification-RCD pathways, such as diagnostic, therapeutic and prognostic potential.
5. Development of effective therapeutic interventions based on RNA modifications and non-apoptotic forms of RCD.
6. Discovery of novel inhibitors or inducers of RNA modifications, and their roles in non-apoptotic forms of RCD.
RNA epitranscriptomics, the study of RNA modifications (pseudouridine (?), 5-methylcytidine (m5C), N1-methyladenosine (m1A), N4-acetylcytidine (ac4C), ribose methylations (Nm) and N 7-methylguanosine (m7G), etc.), is the new frontier of the field. Despite being known since the 1970s, eukaryotic RNA modifications were mostly identified on transfer RNA and ribosomal RNA until the last decade, when they have been identified and characterized on mRNA and various non-coding RNAs. Increasing evidence suggests that RNA modification pathways are also mis-regulated in human diseases and may be ideal targets of disease therapy.
Cells may die from accidental cell death (ACD) or regulated cell death (RCD). ACD is a biologically uncontrolled process, whereas RCD involves tightly structured signaling cascades and molecularly defined effector mechanisms. A growing number of novel non-apoptotic forms of RCD (necroptosis, pyroptosis, ferroptosis, etc.) have been identified and are increasingly being implicated in various human pathologies. RNA modifications can regulate RNA stability and translation and are thus involved in multiple biological activities. Recently, RNA modifications have been shown to have important roles in non-apoptotic forms of RCD.
In this Research Topic, we will concentrate on collecting latest updates about the roles and mechanisms of epitranscriptomic RNA modifications in non-apoptotic forms of RCD in multiple diseases. Also, we highlight the regulatory functions of different RNA modification regulators in the progression or suppression of RCD events and the targeting of these regulators as a potential therapeutic approach for human diseases. We anticipate that our Research Topic will help expand the research community’s knowledge about this recent and rapidly developing field of “epitranscriptomic RNA modification in non-apoptotic forms of regulated cell death” for further thorough studies, which will certainly help manage human diseases.
This Research Topic welcomes all article types. Though not limited to these entirely, we encourage the submission of manuscripts related to the following specific themes:
1. Roles of RNA modifications in non-apoptotic forms of RCD.
2. Biological regulatory mechanisms of RNA modifications in non-apoptotic forms of RCD.
3. The links between RNA modifications and different non-apoptotic forms of RCD pathways in the initiation, progression and therapeutic resistance of human diseases.
4. Clinical application of the target-based RNA modification-RCD pathways, such as diagnostic, therapeutic and prognostic potential.
5. Development of effective therapeutic interventions based on RNA modifications and non-apoptotic forms of RCD.
6. Discovery of novel inhibitors or inducers of RNA modifications, and their roles in non-apoptotic forms of RCD.
